| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000017967 |
| Receipt No. | R000020780 |
| Official scientific title of the study | Clinical study of gemcitabine plus docetaxel in patient with refractory bone and soft tissue sarcomas |
| Date of disclosure of the study information | 2015/06/25 |
| Last modified on | 2018/06/20 (Ver. 5) |
| Basic information | ||
| Official scientific title of the study | Clinical study of gemcitabine plus docetaxel in patient with refractory bone and soft tissue sarcomas | |
| Title of the study (Brief title) | GEM+DTX in patient with sarcomas | |
| Region |
|
|
| Condition | ||
| Condition | bone and soft tissue sarcoma | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Chemotherapy using Ifosfamide, doxorubicin, cisplatin, etoposide, methotrexateis provided for bone and soft tissue sarcomas conventionally. There are some clinical problems that conventional chemotherapy resist tumor, myelosupression and necessity of hospitalization. Gemcitabine and docetaxel are already approved in Japan. The efficacy of chemotherapy with gemcitabine and docetaxel as a second line for refractory bone and soft tissue sarcomas was reported. Chemotherapy with gemcitabine and docetaxel had relatively low risk for myelosupression, this treatment can be indicated in daily out patient clinic. We plan a clinical study of gemcitabine and docetaxel for patient with refractory bone and soft tissue sarcomas. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Others |
| Trial characteristics_2 | |
| Developmental phase | Phase II |
| Assessment | |
| Primary outcomes | tumor response
survival |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | From June 25th, 2015 to December 31th, 2018
Gemcitabine675mg/m2, day1, day8 Docetaxel75mg/m2, day8 3 weeks or more interval |
|
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Establishment of histopathological diagnosis of bone and soft tissue sarcomas
Non responder case with previous 1st line chemotherapy Patient who had enough understanding after explanation of this study and presented document of agreement by their free will |
|||
| Key exclusion criteria | Patient with severe liver or renal dysfunction
Patient with severe interstitial pneumonitis PS4 Pregnant woman Patient who was decided as incompatible by the principal investigator of this study |
|||
| Target sample size | 10 | |||
| Research contact person | |
| Name of lead principal investigator | Torigoe Tomoaki |
| Organization | Juntendo University Urayasu Hospital |
| Division name | Orthopaedic Surgery |
| Address | 2-1-1, Tomioka, Urayasu-city, Chiba, 279-0021 |
| TEL | 047-353-3111 |
| ttorigoe@juntendo.ac.jp | |
| Public contact | |
| Name of contact person | Torigoe Tomoaki |
| Organization | Juntendo University Urayasu Hospital |
| Division name | Orthopaedic Surgery |
| Address | 2-1-1, Tomioka, Urayasu-city, Chiba, 279-0021 |
| TEL | 047-353-3111 |
| Homepage URL | |
| ttorigoe@juntendo.ac.jp | |
| Sponsor | |
| Institute | Juntendo University Urayasu Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Juntendo University Urayasu Hospital |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000020780 |